“I am honored to be a member of the dedicated West Coast Radiology team, where our goal is to provide top-notch patient care. We strive to make the imaging examination and subsequent interpretation as seamless as possible for both our patients and referring physicians.
Robert Princenthal, M.D. is a board-certified radiologist with more than 25 years of experience helping patients better understand the results of their medical imaging studies. Dr. Princenthal is president and founding partner of Rolling Oaks Radiology, a network of outpatient imaging centers in Ventura County, California. He also serves as the medical director for RadNet’s Prostate MRI Program.
Dr. Charles Fiske is the on-site radiologist and medical director for NorCal Imaging Walnut Creek. He is a board-certified radiologist.
A California native from San Diego, Dr. Fiske received his medical degree from the University of California, Los Angeles and completed his residency in radiology at the University of California, San Francisco, where he was chief resident.
According to the American Cancer Society, prostate cancer is the 2nd most common cancer in American men behind skin cancer. Prostate cancer is the 2nd leading cause of cancer death in men behind lung cancer. One man in 6 will be diagnosed with prostate cancer during his lifetime.
In recent years, recommendations for prostate cancer screening have been caught amidst growing controversy. The utility of prostate-specific antigen (PSA) testing, the most prominent front-line screening exam for prostate cancer has been heavily critiqued. Meanwhile, numerous men present with incurable late-stage prostate cancer while men with low-risk, indolent disease receive treatment that offers little benefit in terms of health outcomes.
This is a guest blog post from Mark Scholz, MD. Dr. Scholz is a prostate cancer oncologist and a cofounder of the Prostate Cancer Research Institute. This blog post represents the perspective of Dr. Scholz. We hope you enjoyed this educational article.
This was originally posted at Prostate Snatchers: The Blog.
In a recent study, researchers looked into 12-year follow-up results to the Finnish Prostate Cancer Screening Trial to evaluate the relationship between prostate cancer screening and family history. Although family history is a known risk factor for developing prostate cancer, they curiously found no benefits to selectively screening men based on family history alone.
Recent research shows that new MRI-TRUS fusion biopsy can more effectively detect high-grade prostate cancers than conventional TRUS biopsy.
This is a guest blog post from Mark Scholz, MD. Dr. Scholz is a prostate cancer oncologist and a cofounder of the Prostate Cancer Research Institute. This blog post represents the perspective of Dr. Scholz. We hope you enjoyed this educational article.
New clinical imaging guidelines for the interpretation of prostate MRI exams have been released. A joint steering committee organized by the American College of Radiology, AdMeTech Foundation and European Society of Urogenital Radiology (ESUR) developed Prostate Imaging Reporting and Data System (PI-RADS) Version-2.
